Physician profile
Travis Martinez
NPI 1265012546
$563.10
in general payments reported to CMS, 2019-2025
12 companies · $415 in 2025
The $415 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $148 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $109.04 | 2024-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $100.27 | 2024 | Repatha |
| Glaxosmithkline, LLC. | $71.91 | 2025 | Nucala |
| Shionogi INC | $57.52 | 2025 | Fetroja |
| Merck Sharp & Dohme LLC | $40.14 | 2024-2025 | Winrevair |
| Liquidia Technologies, INC. | $33.79 | 2025 | Yutrepia |
| Genzyme Corporation | $32.20 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $28.91 | 2025 | Uptravi |
| Chiesi USA, INC. | $26.81 | 2025 | Cleviprex |
| Abbvie INC. | $24.00 | 2025 | |
| Medline Industries LP | $20.07 | 2025 | |
| Lilly USA, LLC | $18.44 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.